Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AMRX · against 1,336 other Healthcare companies
Ranked #503 of 1,337 · scores higher than 62% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 60–69, including AMRX · Click a bar to see the companies
Mainly thanks to its EBITDA yield, which is stronger than most Healthcare peers.
| Metric | AMRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 2.4% | 1.5% | 57% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 7.5% | 4.2% | 70% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | -0.2% | -1.0% | 53% | 20% | |
| Book yieldHigher is better · 1,306 reported | 0.5% | 37.9% | 5% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 503 | 16.5B CNY (≈$2.3B) | 62 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 57 |
| 503 | 7.4B CNY (≈$1.0B) | 62 | 42 |
| 503 | 2.9B CNY (≈$409M) | 62 | 51 |
| 503 | 1.5B USD | 62 | 53 |
| 503 | 7.0B USD | 62 | 57 |
| 503 | 179.7B INR (≈$2.2B) | 62 | 74 |
| 503 | 4.7B GBP (≈$6.1B) | 62 | 49 |
| 503 | 84.5B EUR (≈$92.9B) | 62 | 51 |
| 503 | 2.2B USD | 62 | 37 |